12.08.25 -- Grateful Patients Reflect On Therapy And Delivery Advances

Steven Facer and Laxxon Medical COO Klaus Kühne describe the capabilities of 3D screen printing for pharmaceutical production. Explore prototyping, IP protection, release profile possibilities, and more.

Create a simple, modular path to cGMP manufacturing that minimizes risk. Uncover a strategic approach for early-stage development and how it can propel therapies to the clinic and the market.

Consider the pros and cons of marketed amorphous solid dispersions with so-far unpublished data as well as a green alternative to ASDs: best-in-class nanotechnology to manufacture nanocrystals.

Review how Zydis ODT compares against standard oral tablets, how the same molecule can produce a different outcome when utilizing Zydis ODT, and findings from over 20 published studies.

The significant interest in semi-solid systems for the potential of extended release profiles has prompted researchers to develop alternative encapsulating systems.